Please assess the completion status of the following clinical trial:

Trial Title: Nasally Delivered Pulmozyme for Sinusitis in Cystic Fibrosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Clinical and laboratory diagnosis of cystic fibrosis~* Age greater than or equal to 5 years~* Forced expiratory volume in 1 second (FEV1) greater than or equal to 40% predicted~* Sinus surgery within one week of enrollment~Exclusion Criteria:~* Pregnancy~* Intolerance of orally inhaled Pulmozyme (dornase alfa)

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Pulmozyme (Type: EXPERIMENTAL): 2.5 mg Pulmozyme (dornase alfa) delivered intranasally once daily
- placebo (Type: PLACEBO_COMPARATOR): 2.5 mg/2mL placebo administered intranasally once daily

Based on this trial design, predict the completion outcome and termination type (if applicable).